ClinicalTrials.gg
RecruitingNCT01520844CODEXUpdated Apr 7, 2026

the ANRS CO21 " Extreme " Cohort (CODEX)

An interventional study of blood sampling in HIV Infection, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by ANRS, Emerging Infectious Diseases · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2012; still recruiting 14 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases — 12 open to participants now, 13 under way, none of them phase 3. HIV Infections · ANRS, Emerging Infectious Diseases.

Planned enrollment
14th of 50
450 · median 207
Started
2012
with 4 others
No phase
24 of 73
4 open now
Primary completion
2029-09
later than 10 of 12 live
Registered
23rd of 73
by date

Among the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, this one is the 14th largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2012, is one of 24 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 23rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

12 of the 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in HIV Infections by ANRS, Emerging Infectious Diseases, or all of them as a file.
02

Study summary

A consortium of research teams has studied the immunovirological characteristics of these patients:

The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study

Read the detailed description

Two cohorts of patients with a phenotype of HIV resistance exist in France. The ANRS CO15 ALT cohort was set up in 1994. 71 patients were enrolled defined on immunological criteria: CD4 T cell count above 600/mm3 with a stable or increasing count (positive or zero slopes) on at least three consecutive exams performed during the last 5 years whatever the viral load was, with a known HIV infection for at least 8 years. A consortium of research teams has studied the immunovirological characteristics of these patients. After 16 years of follow-up, 6 patients are still actively followed. The main results have shown the lack of deletion in viral genes nor any functional viral defects, a small size for the viral reservoir, and distinctive genetic characteristics of the host (HLA, chemokines) which lead to potent immune cell responses associated with virus control.

The ANRS CO18 HIV Controller cohort set up in 2009 is stemming from the French National Observatory of HIV Controllers which was active between 2006 and 2008 (Study ANRS EP36). 152 patients are enrolled who are defined on virological criteria: the last 5 plasmatic viral loads should be below 400 copies/mL without any antiretroviral treatment, in HIV-infected patients for more than 5 years. A consortium of research teams has studied these patients and has shown that Controllers are infected with replication-competent HIV, that HIV infects CD4 T cells but that the viral replication in CD4 T cells is fully controlled by CD8 T cells.

In addition, the ANRS EP47 VISCONTI study identified 14 patients who had been able to maintain plasmatic viral loads below 400 copies/ml for more than 7 years in the absence of antiretroviral treatment. Differently from HIV controllers, naïve of antiretroviral treatment, the patients from the VISCONTI study started therapy within ten weeks of primary infection and kept it for a median of three years before treatment discontinuation (Post-Treatment Controllers or PTC). The initial analyses revealed important clinical and immunogenetic differences between post-treatment and natural controllers, suggesting that PTC were not naturally predispose to control infection and that they succeeded thanks to initial therapeutic intervention. The mechanisms associated with long-term control in post-treatment controllers also appear different from the main mechanisms identified in HIV controllers. The main objective now is to gather in a common cohort patients with a particular resistance to HIV infection, either with an immunological control (ALT) or a natural (HIV Controllers) or induced virological control (PTC). The enrolled patients will be the patients already enrolled in the cohorts CO15 and CO18, the ANRSEP47 VISCONTI study, and new patients. This will allow common physiopathological studies to precise the mechanisms leading to the virus control and CD4 homeostasy. A better knowledge of the mechanisms of viral control and immune response preservation is very important in the setting of vaccine perspectives and in the perspective of implementing new therapeutic interventions to induce remission of HIV infection. This cohort will allow common research projects with common funding, a better visibility both for clinicians who see patients with unusual phenotypes and for international research. Such a cohort will be unique in the world by its size and the presence of these three complementary groups of patients. The two main objectives for the " Extreme " cohort (ANRS CO21 CODEX) are clinical and immunovirological. We wish to precise the impact of a prolonged untreated HIV infection, to describe the frequency of the "immunological escapes" (CD4 T cell decrease) or "virological escapes" (permanent or transient viral load increase), and to identify predictive markers of HIV control. We wish to study the genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control.

03

Conditions studied

  • HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient infected with -1 and not co-infected with HIV-2
  • Age ≥ 18 at enrollment
  • Able to give written consent
  • Covered by French Social Security
  • accept the constraints imposed by the study
  • without antiretroviral therapy for , HIC and ALT HIC groups and a control of viral load after antiretroviral treatment interruption in PTC group

ALT group: Documented HIV-1 seropositive for at least 8 years with a above 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years regardless of the viral load in the absence of antiretroviral treatment

HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the last 5 viral loads in HIV-RNA consecutive \<400 copies / mL regardless of CD4 count in the absence of antiretroviral treatment

ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years and with the last 5 viral loads in HIV-RNA consecutive \<400 copies / mL in the absence of antiretroviral therapy.

PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of antiretroviral therapy. Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an incomplete P24-positive Western blot) or during the chronic phase of infection, and maintained for at least 12 months in both cases. Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be \<400 copies/mL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies/mL between two viral loads \<400 copies/mL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be \<400 copies/mL

Exclusion criteria

Exclusion Criteria:

Under protection(saving) of justice

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Other
    Cohort study

    Blood sampling

    Biological: blood sampling

Interventions

  • Biologicalblood sampling

    blood sampling

06

What researchers measure

Primary outcomes

  1. clinical and immuno-virological

    Time frame: up to 5 years

Secondary outcomes

  1. mechanisms leading to the virus control and CD4 homeostasy with physiopathological studies

    Time frame: up to 5 years

  2. impact of a prolonged untreated HIV infection,

    Time frame: up to 5 years

  3. frequency of the "immunological escapes" (CD4 T cell decrease) or "virological escapes" (permanent or transient viral load increase)

    Time frame: up to 5 years

  4. genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control

    Time frame: up to 5 years

07

Study locations

1 of 1 sites recruiting
  • Lambotte
    Le Kremlin-Bicêtre, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2012 (actual). Primary completion is estimated for Sep 2029, 211 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 211 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2011
First posted
Jan 30, 2012
StartActual
Feb 2012
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2030
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01520844
Responsible party
Sponsor
First posted
Jan 30, 2012
Start date
Feb 2012
Primary completion
Sep 2029 (estimated)
Completion
Sep 2030 (estimated)
Last update
Apr 7, 2026

Study contacts

Olivier Lambotte, Professor
Contact
olivier.lambotte@bct.aphp.fr
01 49 59 67 54
Faroudy Boufassa
Contact
faroudy.boufassa@inserm.fr
01 45 21 23 65
Olivier Lambotte, Professor
principal investigator · Kremlin Bicetre
Laurence Meyer, Professor
study chair · Methodologist INSERM CESP U1018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion